Finance

Beta
Lists
OGN:NYSE
Organon & Co
$13.36
-0.30%
(-0.040) 1D
$13.36
0.00% (0.00)
After hours
Closed: Jun 5, 4:00:06 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for OGN...
Open
$13.38
High
$13.40
Low
$13.36
Mkt. cap
3.51B
Avg. vol.
11.60M
Volume
2.19M
Dividend
0.60%
Quarterly dividend
$0.02
Ex-dividend date
May 11, 2026
P/E ratio
14.23
52-wk high
$13.48
52-wk low
$5.69
EPS
$0.94
Beta
1.53
Shares outstanding
262.61M
No. of employees
10K
Open
$13.38
High
$13.40
Low
$13.36
Mkt. cap
3.51B
Avg. vol.
11.60M
Volume
2.19M
Dividend
0.60%
Quarterly dividend
$0.02
Ex-dividend date
May 11, 2026
P/E ratio
14.23
52-wk high
$13.48
52-wk low
$5.69
EPS
$0.94
Beta
1.53
Shares outstanding
262.61M
No. of employees
10K
Analyst outlook
Analyst Ratings
Based on 4 analysts giving stock ratings to OGN in the past 3 months
Hold
Buy
0
Hold
4
Sell
0
12 month forecast
Based on 4 Wall Street analysts offering 12 month price targets for OGN in the last 3 months.
Highest
Current $13.36
$14.00 (+4.79%)
Average
$12.33 (-7.71%)
Lowest
$9.00 (-32.63%)
News stories
From sources across the web
Profile
Organon & Co. is an American pharmaceutical company originally founded in Oss, The Netherlands and now headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy, and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States. Wikipedia
About Organon & Co
CEO-
Employees10K
Founded1923
HeadquartersJersey City, New Jersey, United States
SectorPharmaceutical industry
Websiteorganon.com
Last report
Apr 30, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$0.71 / $0.85
-16.82%miss
Revenue / Est. (USD)
1.46B / 1.49B
-1.86%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.59B
1.60B
1.51B
1.46B
Cost of goods sold
701.00M
733.00M
741.00M
670.00M
Cost of revenue
701.00M
733.00M
741.00M
670.00M
Research and development expenses
95.00M
84.00M
91.00M
93.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
453.00M
415.00M
431.00M
424.00M
Operating expense
548.00M
499.00M
522.00M
517.00M
Total operating expenses
1.25B
1.23B
1.26B
1.19B
Operating income
345.00M
370.00M
244.00M
273.00M
Other non operating income
-11.00M
30.00M
-18.00M
15.00M
EBT including unusual items
229.00M
243.00M
-148.00M
213.00M
EBT excluding unusual items
204.00M
255.00M
103.00M
170.00M
Income tax expense
84.00M
83.00M
57.00M
67.00M
Effective tax rate
36.68%
34.16%
-38.51%
31.46%
Other operating expenses
-
-
-
-
Net income
145.00M
160.00M
-205.00M
146.00M
Net profit margin
9.10%
9.99%
-13.60%
10.00%
Earnings per share
1.00
1.01
0.63
0.71
Interest and investment income
-
-
-
-
Interest expense
-131.00M
-128.00M
-121.00M
-111.00M
Net interest expenses
-131.00M
-128.00M
-121.00M
-111.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
434.00M
462.00M
340.00M
359.00M
Gain or loss from assets sale
-
-
-
-81.00M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer